BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23827791)

  • 1. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles.
    Girgis MD; Federman N; Rochefort MM; McCabe KE; Wu AM; Nagy JO; Denny C; Tomlinson JS
    J Surg Res; 2013 Nov; 185(1):45-55. PubMed ID: 23827791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer.
    Girgis MD; Kenanova V; Olafsen T; McCabe KE; Wu AM; Tomlinson JS
    J Surg Res; 2011 Oct; 170(2):169-78. PubMed ID: 21601881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts.
    Rochefort MM; Girgis MD; Knowles SM; Ankeny JS; Salazar F; Wu AM; Tomlinson JS
    Mol Imaging Biol; 2014 Oct; 16(5):721-9. PubMed ID: 24691872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
    Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.
    Houghton JL; Zeglis BM; Abdel-Atti D; Sawada R; Scholz WW; Lewis JS
    J Nucl Med; 2016 Mar; 57(3):453-9. PubMed ID: 26471693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of an αvβ6-specific diabody and a disulfide-stabilized αvβ6-specific cys-diabody.
    White JB; Boucher DL; Zettlitz KA; Wu AM; Sutcliffe JL
    Nucl Med Biol; 2015 Dec; 42(12):945-57. PubMed ID: 26341848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.
    Zettlitz KA; Tsai WK; Knowles SM; Kobayashi N; Donahue TR; Reiter RE; Wu AM
    J Nucl Med; 2018 Sep; 59(9):1398-1405. PubMed ID: 29602820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ImmunoPET Imaging of α
    White JB; Hu LY; Boucher DL; Sutcliffe JL
    Mol Imaging Biol; 2018 Feb; 20(1):103-113. PubMed ID: 28653240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ImmunoPET Imaging of Pancreatic Tumors with
    Sobol NB; Korsen JA; Younes A; Edwards KJ; Lewis JS
    Mol Imaging Biol; 2021 Feb; 23(1):84-94. PubMed ID: 32909244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer.
    Girgis MD; Olafsen T; Kenanova V; McCabe KE; Wu AM; Tomlinson JS
    Int J Mol Imaging; 2011; 2011():834515. PubMed ID: 21912743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.
    McCabe KE; Liu B; Marks JD; Tomlinson JS; Wu H; Wu AM
    Mol Imaging Biol; 2012 Jun; 14(3):336-47. PubMed ID: 21630083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.
    Luo H; England CG; Goel S; Graves SA; Ai F; Liu B; Theuer CP; Wong HC; Nickles RJ; Cai W
    Mol Pharm; 2017 May; 14(5):1646-1655. PubMed ID: 28292180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.
    Wong P; Li L; Chea J; Delgado MK; Poku E; Szpikowska B; Bowles N; Minnix M; Colcher D; Wong JYC; Shively JE; Yazaki PJ
    Cancer Biother Radiopharm; 2017 Sep; 32(7):247-257. PubMed ID: 28910151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.
    Li L; Crow D; Turatti F; Bading JR; Anderson AL; Poku E; Yazaki PJ; Carmichael J; Leong D; Wheatcroft D; Raubitschek AA; Hudson PJ; Colcher D; Shively JE
    Bioconjug Chem; 2011 Apr; 22(4):709-16. PubMed ID: 21395337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
    Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
    J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.